Top entities: KC Pharmaceuticals, United States — Food and Drug Administration, Cardinal Health.

What category does this event fall under?

Regulatory — classified as product recall.

What is the sentiment of coverage?

Aggregate sentiment score: -20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Jul 28, 2026. Coverage continues to evolve.

Regulatory product recall

Major Pharmaceuticals recalls Levothyroxine tablets

Q: When did this event occur?

First reported Jul 27, 2026; last updated Jul 28, 2026.

Q: What is the market impact?

General. The recall may lead to temporary supply shortages of Levothyroxine, potentially affecting patients and pharmacies.

Q: What were the key actions taken?

KC Pharmaceuticals recalled · United States — Food and Drug Administration designated recall KC Pharmaceuticals

Analysis based on 6 articles · First reported Jul 27, 2026 · Last updated Jul 28, 2026

Sentiment

-20

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The recall may lead to temporary supply shortages of Levothyroxine, potentially affecting patients and pharmacies. KC Pharmaceuticals and Cardinal Health could face reputational damage and regulatory scrutiny, but the financial impact is likely limited given the voluntary nature and Class II designation.

Pharmaceuticals

Event Summary

KC Pharmaceuticals voluntarily recalled Levothyroxine Sodium Tablets due to subpotency, meaning the medication may not be fully effective. The recall was designated Class II by the United States — Food and Drug Administration on July 17, indicating possible temporary adverse health consequences. The tablets were packaged in 10-count blister packs and distributed nationwide by KC Pharmaceuticals and also by Cardinal Health. The recall was initiated on July 13, 2026, and affects tablets in various dosages with expiration dates from July 2026 to January 2027. The number of tablets recalled was not disclosed.

Key Actions

70 KC Pharmaceuticals recalled

50 United States — Food and Drug Administration designated recall KC Pharmaceuticals

Entities Involved

priv

KC Pharmaceuticals

KC Pharmaceuticals initiated the voluntary recall of its Levothyroxine tablets due to subpotency, which may harm its reputation and lead to regulatory oversight.

Importance 100.0 Sentiment -30.0

govactor

United States — Food and Drug Administration

The FDA classified the recall as Class II and announced it, fulfilling its regulatory role in ensuring drug safety.

Importance 60.0 Sentiment 0.0

stock

Cardinal Health

Cardinal Health distributed some of the recalled tablets, potentially facing minor reputational impact but no direct liability.

Importance 40.0 Sentiment -10.0

Relationships

KC Pharmaceuticals related ↔ United States — Food and Drug Administration

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard